Axol Bioscience are human cell culture specialists, providing primary cells and iPSC derived cells with a wide range of functionally and physiologically, disease relevant backgrounds, together with optimised media and growth supplements.
Axol Bioscience has raised €6.2M across 2 funding rounds from 7 investors, most recently a round in Jan 2026. Based in Cambridge, UK; active in Healthtech. Data as of 7 Aug 2026.
Timing: in window vs cohort gap · momentum down. Funding-only estimates, not predictions and not investment advice — see signals.
| Date |
|---|
| Stage |
|---|
| Amount |
|---|
| Investors |
|---|
| 2026-01-15 | Other | €2.4M | BroadOak Capital Partners,Roslin Foundation | View deal → |
| 2022-04-08 | Other | €3.8M | Calculus Capital,Dr Jonathan Milner,Meltwind,Par Equity,Scottish Enterprise | View deal → |
